Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were.

Published byTyler Casey Modified over 9 years ago

Similar presentations

Presentation on theme: "Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were."— Presentation transcript:

1 Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were analyzed by an ABL800 FLEX blood gas analyzer, and the values were compared between CRC and non-tumor. Values are means ± SE. See text for details.

2 a b Figure S2 Cytotoxicity of ZnPP (a) and hemin (b) on C26 cells. C26 cells were treated with different concentrations of ZnPP or hemin; percent of dead cells after treatment was determined by MTT assay. Values are means ± SD. Supplemental data Fig. S2

3 Figure S3 Effect of carbon monoxide (a) and heme oxygenase-1 (HO-1) siRNA (b) on chemosensitivity of C26 colon cancer cells to THP. C26 cells were pretreated with HO-1 siRNA (30 nM) for 24h, or carbon monoxide releasing molecule (CORM2, 10 μM) for 1h, and treated by THP for 48h. Cell viability after treatment was determined by MTT assay, and the data was described as the percent viability of cells under different treatments. Vehicle indicates the result for cells treated with TransMessenger Transfection Reagent only (without siRNA); siRNA indicates the result for cells transfected with siRNA for HO-1 mRNA. Inset of (b) shows the results of RT-PCR of HO-1 in C26 cells treated by HO-1 siRNA. Values are means ± SD. * P < 0.05, ** P < 0.01. See text for details. Supplemental data Fig. S3 Vehicle siRNA b * ** a * *

4 Figure S4 Cytotoxicity assay of THP with/without hemin or ZnPP using LDH cytotoxicity assay kit in C26 cells. C26 cells were treated with different concentrations of THP in the presence/absence of hemin (1 μM) or HO inhibitor ZnPP (0.5 μM); percent of dead cells after treatment was determined by LDH cytotoxicity assay. Values are means ± SD. Supplemental data Fig. S4

Download ppt "Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were."

Similar presentations

G-Fectin TM 1. A novel transfection reagent developed by Genolution 2.Cationic lipid based 3. no cell splitting is required 4. Whole transfection can be.

G-Fectin TM 1. A novel transfection reagent developed by Genolution 2.Cationic lipid based 3. no cell splitting is required 4. Whole transfection can be.
Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.

Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.
Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.
Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.

Supplemental Figure cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.
Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.
Supplemental Figures Byrne et al. Metabolic vulnerabilities in endometrial cancer.

Supplemental Figures Byrne et al. Metabolic vulnerabilities in endometrial cancer.
Marker (%) Normal EPCs Mean ± SM (%) MMD EPCs Mean ± SM (%) CD3426.9 ± 11.531.0 ± 6.8 KDR27.3 ± 5.5222.4 ± 8.90 CD13324.5 ± 4.6412.6 ± 3.93 CD3199.0 ±

Marker (%) Normal EPCs Mean ± SM (%) MMD EPCs Mean ± SM (%) CD ± ± 6.8 KDR27.3 ± ± 8.90 CD ± ± 3.93 CD ±
10 h5 h 0 h Supplemental Figure 1 14 h 16 h 24 h Untreated Supplemental Figure 1 Untreated cells were analyzed using live cell imaging microscopy. Time.

10 h5 h 0 h Supplemental Figure 1 14 h 16 h 24 h Untreated Supplemental Figure 1 Untreated cells were analyzed using live cell imaging microscopy. Time.
Supplementary Figure 1A-B A H1299 RH1299 0 15 30 45 60 0 45 80 160 200 LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.

Supplementary Figure 1A-B A H1299 RH LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.
Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.

Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.
Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Fig. S1 Fig. S1. Experimental design of DSS-induced colitis (A) and AOM/DSS-induced colon carcinogenesis (B).

Fig. S1 Fig. S1. Experimental design of DSS-induced colitis (A) and AOM/DSS-induced colon carcinogenesis (B).
SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.
Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.

Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.
SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell lines Supplemental Fig. S2 Multiple E:T ratio for.

SNU423 SK-Hep1 HepG2 HA22T AR GAPDH Supplemental Fig. S1 Endogenous AR expression in various HCC cell lines Supplemental Fig. S2 Multiple E:T ratio for.
Products > U87 Transfection Reagent (Glioblastoma Cells) Altogen Biosystems offers the U87 Transfection Reagent among a host of 100+ cell line specific.

Products > U87 Transfection Reagent (Glioblastoma Cells) Altogen Biosystems offers the U87 Transfection Reagent among a host of 100+ cell line specific.
1A 1B 1C 1D Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1, induced angiogenesis in vitro. (A and B) Treatment.

1A 1B 1C 1D Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1, induced angiogenesis in vitro. (A and B) Treatment.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.

Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.

Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.
Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Similar presentations

Ads by Google